ClinicalTrials.gg
RecruitingNCT07030140Updated Oct 15, 2026

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

A Phase 2 interventional study of Stereotactic Body Radiotherapy (SBRT) and Tislelizumab in Cholangiocarcinoma, Hilar Cholangiocarcinoma and Bile Duct Cancer, sponsored by Jinbo Yue. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionKlatskin TumorRegistry: CholangiocarcinomaReclassifiedWhy we changed it
Registry
Cholangiocarcinoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Klatskin Tumor
Why
  1. The study's listed conditions name Klatskin Tumor, a narrower term within Cholangiocarcinoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jinbo Yue · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Klatskin Tumor with a site in China — 9 open to participants now, 11 under way, 1 of them phase 3. Klatskin Tumor · China.

Planned enrollment
15th of 22
38 · median 61
Started
2025
the only one that year
Phase 2
8 of 29
3 open now
Primary completion
2027-07
later than 5 of 10 live
Registered
25th of 29
by date

Among the 29 studies in Klatskin Tumor with a site in China, this one is the 15th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2025, is one of 8 in phase 2, reaches primary completion later than 5 of the 10 other live ones, and was the 25th registered.

Klatskin Tumor

82 studies on the registry are indexed under Klatskin Tumor; 27 are open to participants now.

Browse Klatskin Tumor studies →

Open to participants now

9 of the 29 studies in Klatskin Tumor with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Klatskin Tumor studies recruiting now, 11 (58%) set no upper age limit and 5 (26%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Klatskin Tumor with a site in China, or all of them as a file.
02

Study summary

This is a phase II, single-arm, prospective clinical trial designed to evaluate the efficacy and safety of neoadjuvant therapy combining stereotactic body radiotherapy (SBRT), GP chemotherapy (gemcitabine and cisplatin/oxaliplatin), and tislelizumab in patients with borderline resectable or unresectable hilar cholangiocarcinoma. Eligible patients will receive SBRT followed by three cycles of tislelizumab plus GP chemotherapy. Patients with resectable disease after evaluation may undergo surgery and receive postoperative treatment as recommended by the multidisciplinary team. Those who remain unresectable will receive three additional cycles of systemic therapy. The primary endpoint is overall survival (OS); secondary endpoints include R0 resection rate, pathological complete response (pCR), surgical difficulty, progression-free survival (PFS), local control rate, and treatment-related safety.

Read the detailed description

Hilar cholangiocarcinoma is a rare but highly aggressive malignancy, often diagnosed at advanced stages due to its asymptomatic progression and challenging anatomical location. R0 resection remains the cornerstone of curative therapy, but many patients are initially considered borderline resectable or unresectable due to vascular involvement or lymph node metastasis.

Recent studies suggest that neoadjuvant therapy may improve resectability and survival outcomes by reducing tumor burden and modulating the tumor microenvironment. Stereotactic body radiotherapy (SBRT) offers precise local control, while GP chemotherapy (gemcitabine and cisplatin/oxaliplatin) has demonstrated efficacy in biliary tract cancers. Immunotherapy with PD-1 inhibitors, such as tislelizumab, has shown promise in enhancing antitumor immunity, especially when combined with radiotherapy and chemotherapy.

This phase II, single-arm, prospective study aims to evaluate the efficacy and safety of neoadjuvant SBRT followed by tislelizumab and GP chemotherapy in patients with borderline resectable or unresectable hilar cholangiocarcinoma. Patients will first receive SBRT to the gross tumor volume (GTV) at a dose of either 5Gy × 5-8 fractions or 4Gy × 15 fractions. After radiotherapy, participants will receive three cycles of tislelizumab (200mg Q3W) in combination with gemcitabine (1000mg/m² on Days 1 and 8) and cisplatin (25mg/m² on Days 1 and 8) or oxaliplatin (100mg/m² on Day 1), repeated every 21 days.

Patients will be re-evaluated after three cycles. If resectable, patients may undergo surgery, followed by additional postoperative therapy based on MDT recommendations. If unresectable, an additional three cycles of systemic therapy will be administered. The primary endpoint is overall survival (OS). Secondary endpoints include R0 resection rate, pathological complete response (pCR), surgical difficulty, local control rate, progression-free survival (PFS), and treatment-related adverse events.

03

Conditions studied

  • Cholangiocarcinoma
  • Hilar Cholangiocarcinoma
  • Bile Duct Cancer

Browse trials for

Keywords

  • Borderline Resectable
  • Unresectable
  • SBRT
  • Tislelizumab
  • Gemcitabine
  • Cisplatin
  • Oxaliplatin
  • Neoadjuvant Therapy
  • Immunotherapy
  • Radiation Therapy
  • PD-1 Inhibitor
  • Biliary Tract Cancer
04

In context

Klatskin Tumor Reclassified

82 studies on the registry are indexed under Klatskin Tumor; 27 are open to participants now.

This study's planned enrollment of 38 is below the median of 55 across 56 interventional studies indexed under Klatskin Tumor.

Browse Klatskin Tumor studies →

Lead sponsor

Jinbo Yue is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Compared within Klatskin Tumor, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cholangiocarcinoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years, or cytologically confirmed hilar cholangiocarcinoma
  • Borderline resectable or unresectable disease based on imaging and MDT evaluation
  • performance status 0-1
  • Adequate hematologic, hepatic, and renal function
  • No prior anti-tumor therapy for current diagnosis
  • Expected survival ≥ 3 months
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Evidence of distant
  • Prior treatment with
  • Uncontrolled infection or serious medical comorbidities
  • Active disease requiring systemic therapy
  • History of organ transplantation or immunodeficiency
  • Pregnancy or lactation
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Tislelizumab + SBRT + GP Chemotherapy

    Participants will receive neoadjuvant hypofractionated radiotherapy followed by six cycles of combination therapy with tislelizumab and GP chemotherapy. RT: 5 Gy × 5-8 fractions or 3.5-4.0 Gy × 15 fractions to the primary tumor. Tislelizumab: 200 mg intravenously every 3 weeks (Day 1 of each cycle). Gemcitabine: 1000 mg/m² IV on Days 1 and 8 of each 21-day cycle. Cisplatin: 25 mg/m² IV on Days 1 and 8 OR Oxaliplatin: 100 mg/m² IV on Day 1 (based on clinical condition). After six cycles, patients will undergo tislelizumab maintainese (Totally one year).

    Radiation: Stereotactic Body Radiotherapy (SBRT) · Drug: Tislelizumab · Drug: Gemcitabine · Drug: Cisplatin or Oxaliplatin

Interventions

  • RadiationStereotactic Body Radiotherapy (SBRT)

    SBRT to the primary tumor and metastatic lymph node at a dose of either 5 Gy × 5-8 fractions or 4 Gy × 15 fractions, delivered prior to systemic therapy.

  • Tislelizumab 200 mg administered intravenously every 3 weeks (on Day 1 of each 21-day cycle), for six cycles depending on surgical eligibility.

  • Gemcitabine 1000 mg/m² administered intravenously on Days 1 and 8 of each 21-day cycle, for six cycles.

  • DrugCisplatin or Oxaliplatin

    Cisplatin 25 mg/m² on Days 1 and 8 or oxaliplatin 100 mg/m² on Day 1 of each 21-day cycle, selected based on patient condition, for six cycles.

07

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Defined as the time from initiation of treatment to death from any cause.

    Time frame: Up to 36 months

Secondary outcomes

  1. R0 Resection Rate

    Proportion of patients achieving microscopically margin-negative (R0) resection among those undergoing surgery.

    Time frame: At the time of surgery (approx. 3-6 months from enrollment)

  2. Pathological Complete Response (pCR)

    Absence of residual viable tumor cells in resected specimens.

    Time frame: At the time of surgery

  3. Progression-Free Survival (PFS)

    Time from initiation of treatment to disease progression or death from any cause.

    Time frame: Up to 24 months

  4. Local Control Rate

    Proportion of patients without local tumor progression at irradiated site.

    Time frame: 6, 12, 18, and 24 months

  5. Treatment-related Adverse Events

    Frequency and severity of adverse events graded by CTCAE v5.0.

    Time frame: From treatment initiation up to 90 days after last dose

08

Study locations

1 of 1 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jun 22, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and arm descriptions
1 update, last Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Minor edits only
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07030140
Lead sponsor
Jinbo Yue
Responsible party
Jinbo Yue (Chief Physician, Radiation Oncology, Shandong Cancer Hospital and Institute) — Sponsor-investigator
First posted
Jun 22, 2025
Start date
Jul 1, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Jinbo Yue
Contact
jbyue@sdfmu.edu.cn
053167626442
Jinbo Yue
principal investigator · Shandong Cancer Hospital and Institute
Bo Zhang
study chair · Shandong Cancer Hospital and Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tislelizumab · Gemcitabine

Start the discussion